Supernus Pharmaceuticals (Supernus Pharmaceuticals) FCF Margin % : 27.38% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Supernus Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Supernus Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2023 was $45.0 Mil. Supernus Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $164.3 Mil. Therefore, Supernus Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 27.38%.

As of today, Supernus Pharmaceuticals's current FCF Yield % is 6.72%.

The historical rank and industry rank for Supernus Pharmaceuticals's FCF Margin % or its related term are showing as below:

SUPN' s FCF Margin % Range Over the Past 10 Years
Min: -27.07 Med: 23.94 Max: 37.26
Current: 18.19

During the past 13 years, the highest FCF Margin % of Supernus Pharmaceuticals was 37.26%. The lowest was -27.07%. And the median was 23.94%.

SUPN's FCF Margin % is ranked better than
88.89% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs SUPN: 18.19

Supernus Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Supernus Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals FCF Margin % Chart

Supernus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

36.09

25.89

21.57

17.45

18.19

Supernus Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															16.48	31.77	-14.04	23.22	27.38

Competitive Comparison of Supernus Pharmaceuticals's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Supernus Pharmaceuticals's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's FCF Margin % falls into.

Supernus Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Supernus Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	110.534	/	607.521
	=	18.19 %

Supernus Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	44.994	/	164.314
	=	27.38 %

Supernus Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Supernus Pharmaceuticals (Supernus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (NAS:SUPN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

S49:Germany

Address

9715 Key West Avenue, Rockville, MD, USA, 20850

Website

https://www.supernus.com

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Executives

Tami Tillotson Martin	officer: Sr. V.P., Regulatory Affairs	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Newhall Charles W Iii	director	1119 ST PAUL ST, BALTIMORE MD 21202
Frederick M. Hudson	director	9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Frank Mottola	officer: Sr VP, Quality, GMP Oper. & IT	9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Bethany Sensenig	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Jack A. Khattar	director, officer: President, CEO	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Padmanabh P. Bhatt	officer: Sr. VP of IP, CSO	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Timothy C Dec	officer: Senior Vice-President & CFO	C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Jonathan Rubin	officer: SVP, Chief Medical Officer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Schwabe Stefan K.f.	officer: Executive Vice President R&D	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gregory S Patrick	officer: VP, Chief Financial Officer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
James Patrick Kelly	officer: Executive Vice-President & CFO	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Carrolee Barlow	director	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Victor Vaughn	officer: Sr. VP of Sales	C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
M James Barrett	director, 10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202